MX2022013152A - Composiciones y métodos para prevenir, controlar y diagnosticar infecciones por micobacterias. - Google Patents

Composiciones y métodos para prevenir, controlar y diagnosticar infecciones por micobacterias.

Info

Publication number
MX2022013152A
MX2022013152A MX2022013152A MX2022013152A MX2022013152A MX 2022013152 A MX2022013152 A MX 2022013152A MX 2022013152 A MX2022013152 A MX 2022013152A MX 2022013152 A MX2022013152 A MX 2022013152A MX 2022013152 A MX2022013152 A MX 2022013152A
Authority
MX
Mexico
Prior art keywords
compositions
preventing
controlling
methods
mycobacterial infections
Prior art date
Application number
MX2022013152A
Other languages
English (en)
Inventor
Andrew Potter
Antonio Facciuolo
Philip Griebel
Neil Rawlyk
Jeffrey Chen
Elodie Pastural
Manjeet Bains
Michael Trimble
Amy Lee
Robert Hancock
Volker Gerdts
Original Assignee
Univ Saskatchewan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Saskatchewan filed Critical Univ Saskatchewan
Publication of MX2022013152A publication Critical patent/MX2022013152A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen antígenos de micobacterias, como MAP y antígenos de M. bovis; los antígenos se pueden usar en composiciones de subunidades para provocar respuestas inmunes para prevenir y/o controlar infecciones micobacterianas, así como en diagnósticos para detectar mamíferos infectados con micobacterias.
MX2022013152A 2020-04-20 2021-04-19 Composiciones y métodos para prevenir, controlar y diagnosticar infecciones por micobacterias. MX2022013152A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063012668P 2020-04-20 2020-04-20
PCT/CA2021/050527 WO2021212215A1 (en) 2020-04-20 2021-04-19 Compositions and methods for preventing, controlling and diagnosing mycobacterial infections

Publications (1)

Publication Number Publication Date
MX2022013152A true MX2022013152A (es) 2023-02-09

Family

ID=78270853

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013152A MX2022013152A (es) 2020-04-20 2021-04-19 Composiciones y métodos para prevenir, controlar y diagnosticar infecciones por micobacterias.

Country Status (8)

Country Link
US (1) US20230218734A1 (es)
EP (1) EP4138894A4 (es)
AU (1) AU2021258911A1 (es)
BR (1) BR112022021258A2 (es)
CA (1) CA3176303A1 (es)
CL (1) CL2022002893A1 (es)
MX (1) MX2022013152A (es)
WO (1) WO2021212215A1 (es)

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310550A (en) 1979-10-26 1982-01-12 Pfizer Inc. Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
US4744984A (en) 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US5985354A (en) 1995-06-07 1999-11-16 Brown University Research Foundation Preparation of multiwall polymeric microcapsules from hydrophilic polymers
US5151267A (en) 1988-07-15 1992-09-29 University Of Saskatchewan Bovine herpesvirus type 1 polypeptides and vaccines
US5053451A (en) 1990-01-19 1991-10-01 The Pennsylvania Research Corporation Ionically cross-linkable polyphosphazene: poly(bis(carboxylatophenoxy) phosphazene) and its hydrogels and membranes
US5149543A (en) 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
US5951988A (en) 1993-03-30 1999-09-14 University Of Saskatchewan Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods
US5562909A (en) 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
US5855895A (en) 1995-06-07 1999-01-05 Virus Research Institute Polyphosphazene polyelectrolyte immunoadjuvants
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5807757A (en) 1996-07-02 1998-09-15 Virus Research Institute, Inc. Preparation of ionically cross-linked polyphosphazene microspheresy by coacervation
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
PT1449922E (pt) * 1997-04-02 2007-11-09 Statens Seruminstitut Fragmentos de ácidos nucleicos e fragmentos polipeptídicos obtidos a partir de m. tuberculosis
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
EP1029053A1 (en) * 1997-11-10 2000-08-23 Statens Seruminstitut Nucleic acid fragments and polypeptide fragments derived from mycobacterium tuberculosis
US6207171B1 (en) 1998-03-27 2001-03-27 Avant Immunotherapeutics, Inc. Polyphosphazene microspheres
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6261573B1 (en) 1998-10-30 2001-07-17 Avant Immunotherapeutics, Inc. Immunoadjuvants
NZ517928A (en) 1999-09-27 2004-09-24 Coley Pharm Gmbh Methods related to immunostimulatory nucleic acid-induced interferon
ES2314099T3 (es) 2001-08-17 2009-03-16 Coley Pharmaceutical Gmbh Oligonucleotidos inmunoestimulantes con motivos combinados con actividad mejorada.
EP1478371A4 (en) 2001-10-12 2007-11-07 Univ Iowa Res Found METHOD AND PRODUCTS FOR IMPROVING IMMUNE RESPONSES WITH IMIDAZOCHINOLINE COMPOUNDS
US7074559B2 (en) * 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
WO2007108829A2 (en) * 2005-10-26 2007-09-27 Gene Therapy Systems, Inc. Tuberculosis nucleic acids, polypeptides and immunogenic compositions
US8465753B2 (en) * 2007-04-23 2013-06-18 Robert J. Greenstein Combination vaccines against Mycobacterium sp. and methods of using the same
US7846420B2 (en) * 2007-04-23 2010-12-07 Greenstein Robert J Mycobacterium avium subspecies paratuberculosis vaccines and methods of using the same
US20130333068A1 (en) * 2008-04-29 2013-12-12 Marie Coffin Genes and uses for plant enhancement
AU2009304552B2 (en) 2008-10-16 2015-02-19 Dalhousie University Combination adjuvant formulation
EP2437061A1 (en) * 2010-09-30 2012-04-04 Ikonomopoulos, John Mycobacterial protein detection
WO2019144139A1 (en) * 2018-01-22 2019-07-25 Oregon State University Immunogenic compositions comprising mycobacterium bovis surface proteins and uses thereof
CN110606875A (zh) * 2019-09-20 2019-12-24 中国农业科学院兰州兽医研究所 一种用于制备口蹄疫疫苗的分子内佐剂及其应用和口蹄疫疫苗

Also Published As

Publication number Publication date
CL2022002893A1 (es) 2023-06-30
AU2021258911A1 (en) 2022-11-24
WO2021212215A1 (en) 2021-10-28
BR112022021258A2 (pt) 2023-01-17
EP4138894A1 (en) 2023-03-01
US20230218734A1 (en) 2023-07-13
EP4138894A4 (en) 2024-06-26
CA3176303A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
Tkachuk et al. Multi-subunit BCG booster vaccine GamTBvac: Assessment of immunogenicity and protective efficacy in murine and guinea pig TB models
WO2014063704A3 (en) M. tuberculosis vaccines
MX2018014270A (es) Composiciones y metodos para tratar la tuberculosis secundaria e infecciones po micobacteria no tuberculosa.
MX2021000285A (es) Composiciones que comprenden cepas bacterianas.
PH12020550941A1 (en) Methods and compositions to prevent microbial infection
MX2020004094A (es) Metodos para administrar inmunoterapia con receptores de antigeno quimerico.
BR112016023778A2 (pt) proteína de fusão ou coquetel antígeno, uso de uma proteína de fusão ou coquetel antígeno, vacina, e método para a imunização de um animal, incluindo um ser humano, contra a tuberculose causada por micobactérias virulentas
MY173004A (en) Mycobacterial antigen vaccine
Bai et al. Prolonged intervals during Mycobacterium tuberculosis subunit vaccine boosting contributes to eliciting immunity mediated by central memory-like T cells
MX393266B (es) Composiciónpara usarse en terapia de microbiota
BR112016016103A2 (pt) Composição de antígenos micobacterianos
MX2022014984A (es) Atenuacion de virulencia bacteriana mediante atenuacion de transporte de folato bacteriano.
PH12021552070A1 (en) Lawsonia intracellularis compositions and methods of using the same
WO2019113509A3 (en) Methods for enhancing and maintaining car-t cell efficacy
WO2020232141A3 (en) Compositions and methods for treating t cell exhaustion
Rao et al. Increased expression of Mycobacterium tuberculosis 19 kDa lipoprotein obliterates the protective efficacy of BCG by polarizing host immune responses to the Th2 subtype
EA202190876A1 (ru) Композиции, содержащие бактериальные штаммы
CL2022002893A1 (es) Composiciones y métodos para prevenir, controlar y diagnosticar infecciones por micobacterias
Triccas Recombinant BCG as a vaccine vehicle to protect against tuberculosis
EP4635510A3 (en) Combination vaccine
MY193450A (en) Obtaining high-performance yeast strains for metabolizing arabinose
ATE335505T1 (de) Saponin inaktivierte mykoplasma impfstoffe
WO2022008973A3 (en) Compositions, methods, and systems for detecting immune response
BR112021024655A2 (pt) Reagente de diagnóstico
MX2020005104A (es) Composiciones de vacuna para uso contra dermatitis digital en un mamifero.